A Phase 2 Study of MZE782 in Adults With PKU

Part of paid clinical trials in Gordonville, Pennsylvania.

Sponsor
Maze Therapeutics
Study ID
NCT07694440
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Phenylketonuria (PKU)

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • MZE782 — DRUG
    Tablet, Low Dose
  • Placebo — OTHER
    Tablet
  • MZE782 — DRUG
    Tablet, High Dose

Study Details

The purpose of this study is to evaluate the safety, tolerability, and efficacy of MZE782 in adults with Phenylketonuria (PKU).

Key Dates

First listed
Jul 10, 2026
Start date
Jun 23, 2026
Status verified
Jul 2026
Primary completion
Dec 31, 2027
Completion
Feb 29, 2028

Study Design

Enrollment
38 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: MZE782 Low Dose (Cohort 1A)
  • Placebo Comparator: Placebo (Cohort 1A)
  • Experimental: MZE782 High Dose (Cohort 1B)
  • Placebo Comparator: Placebo (Cohort 1B)
  • Experimental: MZE782 High Dose (Cohort 2)
  • Placebo Comparator: Placebo (Cohort 2)

Primary Outcome Measure

Safety and tolerability based on incidence of adverse events (AEs) [ Time Frame: Week 0 to Week 17 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Clinic for Special ChildrenGordonvillePennsylvania17529-

Find similar trials in Gordonville, PA

By research site
Clinic for Special Children· Gordonville, PA

Related Studies